Novel NMDA/glycine site antagonists attenuate cocaine-induced behavioral toxicity

European Journal of Pharmacology

Volumn 338, Issue 3, 1997, Pages 233-242

  Matsumoto, Rae R ^a,b   Brackett, Ryan L ^a   Kanthasamy, Anumantha G ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cocaine; Convulsion; Lethality; NMDA receptor; Toxicity

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DICHLORO 2,3 QUINOXALINEDIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 6,7 DIMETHYL 5 NITRO 2,3 QUINOXALINEDIONE; COCAINE; CYCLOSERINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVULSION; INTRAPERITONEAL DRUG ADMINISTRATION; LETHALITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030690442     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)81926-7     Document Type: Article

References (45)

1. Auer R.N. Structural neurotoxicological investigation of the glycine antagonist 5-nitro-6,7-dichloroquinoxalinedione (ACEA-1021). Neurotoxicology. 18:1997;53-62.
2. Balster R.L., Mansbach R.S., Shelton K.L., Nicholson K.L., Grech D.M., Wiley J.L., Li H., Weber E. Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav. Pharmacol. 6:1995;577-589.
3. Benowitz N.L. Clinical pharmacology and toxicology of cocaine. Pharmacol. Toxicol. 72:1993;3-12.
4. Berger I., Gillis R.A., Vitagliano S., Panico W.H., Magee S., Kelly M., Norman W.P., McManigle J.E., Taveira DaSilva A.M. NMDA receptors are involved at the ventrolateral nucleus tractus solitarii for termination of inspiration. Eur. J. Pharmacol. 277:1995;195-208.
5. Bitner R.S., Kanthasamy A., Isom G.E., Kim G.Y. Seizures and selective CA-1 hippocampal lesions induced by an excitotoxic cyanide metabolite, 2-iminothiazolidine-4-carboxylic acid. Neurotoxicology. 16:1995;115-122.
6. Carter A.J. Many agents that antagonize the NMDA receptor-channel complex in vivo also causes disturbances of motor coordination. J. Pharmacol. Exp. Ther. 269:1994;573-580.
7. Cavazos J.E., Das I., Sutula T.P. Neuronal loss induced in limbic pathways by kindling: Evidence for induction of hippocampal sclerosis by repeated brief seizures. J. Neurosci. 14:1994;3106-3121.
8. Collingridge, G.L., Watkins, J.C., 1994. The NMDA Receptor. Oxford, New York, NY.
9. Derlet R.W., Albertson T.E. Anticonvulsant modification of cocaine-induced toxicity in the rat. Neuropharmacology. 29:1990;255-259.
10. Dietrich W.D. The importance of brain temperature in cerebral injury. J. Neurotrauma. 9 (Suppl. 2):1992;S475-485.
11. Hargreaves R.J., Rigby M., Smith D., Hill R.G. Lack of effect of L-687-414 (+)-cis-4-methyl-HA-966, an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br. J. Pharmacol. 110:1993;36-42.
12. Hawkinson J.E., Huber K.R., Sahota P.S., Hsu H.H., Weber E., Whitehouse M.J. The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain. Brain Res. 744:1997;227-234.
13. Itzhak I., Stein I. Sensitization to the toxic effects of cocaine in mice is associated with the regulation of N-methyl-D-aspartate receptors in the cortex. J. Pharmacol. Exp. Ther. 262:1992;464-470.
14. Johnson D.N., Vocci F. Medications development at the National Institute on Drug Abuse: Focus on cocaine. NIDA Res. Monogr. 135:1993;57-70.
15. Kanthasamy A., Truong D.D., Vu T.Q., Kanthasamy A.G. Neuroprotective effects of novel strychnine-insensitive glycine site antagonists in experimental Parkinson's models. Soc. Neurosci. Abstr. 22:1996;832.16.
16. Keana J.F.W., Kher S.M., Cai S.X., Dinsmore C.M., Glenn A.G., Guastella J., Huang J.-C., Ilyin V., Lu Y., Mouser P.L., Woodward R.M., Weber E. Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-glutamate receptors. J. Med. Chem. 38:1995;4367-4379.
17. Koek W., Colpaert F.C. Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: Relationship with phencyclidine-like behavioral effects. J. Pharmacol. Exp. Ther. 252:1990;349-357.
18. Lallement G., Delamanche I.S., Fernot-Marino I., Baubichon D., Denoyer M., Carpentier P., Blanchet G. Neuroprotective activity of glutamate receptor antagonists against soman-induced hippocampal damage: Quantification with an omega 3 site ligand. Eur. J. Pharmacol. 618:1993;227-237.
19. Lippert K., Welsch M., Krieglstein J. Over-additive protective effect of dizocilpine and NBQX against neuronal damage. Eur. J. Pharmacol. 253:1994;207-213.
20. Löscher W., Hönack D. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: Comparisons with diazepam and interactions with flumazenil. Br. J. Pharmacol. 113:1994;1349-1357.
21. Lutfy K., Shen K.Z., Kwon I.K., Cai S.X., Woodward R.M., Keana J.F.W., Weber E. Blockade of morphine tolerance in mice by ACEA-1328, a novel NMDA receptor/glycine site antagonist. Eur. J. Pharmacol. 273:1995;187-189.
22. Lutfy K., Shen K.Z., Woodward R.M., Weber E. Inhibition of morphine tolerance by NMDA antagonists in the formalin test. Brain Res. 731:1996;171-181.
23. Lutfy K., Weber E. Attenuation of nociceptive responses by ACEA-1021, a competitive NMDA receptor/glycine site antagonist, in the mice. Brain Res. 743:1996;17-23.
24. Matsumoto R.R., Nguyen D.C., Truong D.D. Strychnine-insensitive glycine site antagonists attenuate a cardiac arrest-induced movement disorder. Eur. J. Pharmacol. 275:1995;117-123.
25. Meldrum B.S. The role of glutamate in epilepsy and other CNS disorders. Neurology. 44 (Suppl. 8):1994;S14-23.
26. Olney J.W., Collins R.C., Sloviter R.S. Excitotoxic mechanisms of epileptic brain damage. Adv. Neurol. 44:1986;857-877.
27. Savolainen K., Hirvonen M.R., Naarala J. Phosphoinositide second messengers in cholinergic excitotoxicity. Neurotoxicology. 15:1994;493-502.
28. Sheardown M.J., Nielsen E.O., Hansen A.J., Jacobsen P., Honore T. 2,3-Dihydroxy-6-nitro-sulfamoyl-benzo(F)quinoxaline: A neuroprotectant for cerebral ischemia. Science. 247:1990;571-574.
29. Shimosato K., Watnabe S., Marley R.J., Saito T. One-way cross sensitization and cross-tolerance to seizure activity from cocaine to lidocaine. Ann. N. Y. Acad. Sci. 801:1996;340-352.
30. Singh L., Donald A.E., Foster A.C., Hutson P.H., Iversen L.L., Iversen S.D., Kemp J.A., Leeson P.D., Marshall G.R., Oles R.J., Priestley T., Thorn L., Tricklebank M.D., Vass C.A., Williams B.J. Enantiomers of HA-966 (3-amino-1-hydroxypyrrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (-)-HA-966 is a potent γ-butyrolactone-like sedative. Proc. Natl. Acad. Sci. USA. 87:1990;347-351.
31. Shimizu-Sasamata M., Kawasaki-Yatsugi S., Okaka M., Sakamoto S., Yatsugi S., Togami J., Hatanaka K., Ohmori J., Koshiya K., Usuda S., Murase K. YM90K: Pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionate/kainate receptor antagonist. J. Pharmacol. Exp. Ther. 276:1996;84-92.
32. Smith S.E., Durmuller N., Meldrum B.S. The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur. J. Pharmacol. 201:1991;179-183.
33. Taylor C.P., Vartanian M.G. Probenecid pretreatment enhances anticonvulsant action of NBQX in mice. Eur. J. Pharmacol. 213:1992;151-153.
34. Turski L., Jacobsen P., Honore T., Stephens D.N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline. J. Pharmacol. Exp. Ther. 260:1992;742-747.
35. Vaccarino A.L., Marek P., Kest B., Weber E., Keana J.F.W., Liebeskind J.C. NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res. 615:1993;331-334.
36. Warner D.S., Martin H., Ludwig P., McAllister A., Keana J.F.W., Weber E. In vivo models of cerebral ischemia: Effects of parenterally administered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab. 15:1995;188-196.
37. Wasterlain C.G., Shirasaka Y. Seizures, brain damage and brain development. Brain Dev. 16:1994;279-295.
38. Watson G.B., Bolanowski M.A., Baganoff M.P., Deppeler C.L., Lanthorn T.H. D-cycloserine acts a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 510:1990;158-160.
39. West M., Huang W. Spinal cord excitatory amino acids and cardiovascular autonomic responses. Am. J. Physiol. 267:1994;H865-873.
40. Wetli C.V., Fishbain D.A. Cocaine-induced psychosis and sudden death in recreational cocaine users. J. Forensic Sci. 30:1985;873.
41. Witkin J.M., Tortella F.C. Modulators of N-methyl-D-aspartate protect against diazepam- or phenobarbital-resistant cocaine convulsions. Life Sci. 48:1991;PL51-56.
42. Wood P.L. The co-agonist concept: Is the NMDA-associated glycine receptor saturated in vivo? Life Sci. 57:1995;301-310.
43. Woodward R.M., Huettner J.E., Guastella J., Keana J.F.W., Weber E. In vitro pharmacology of ACEA-1021 and ACEA-1031: Systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol. Pharmacol. 47:1995;568-581.
44. Woodward R.M., Huettner J.E., Tran M., Guastella J., Keana J.F.W., Weber E. Pharmacology of 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione: A novel systemically active ionotropic glutamate receptor antagonist. J. Pharmacol. Exp. Ther. 275:1995;1209-1218.
45. Zarnowski T., Kleinrok Z., Turski W.A., Czuczwar S.J. 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline enhances the protective activity of common anti-epileptic drugs against maximal electroshock-induced seizures in mice. Neuropharmacology. 32:1993;895-900.